General description
INN
Prednisone
Medicine type
Chemical agent
EML status history
First added in 2021
(TRS
1035)
for
Allergic or hypersensitivity conditions of unspecified type
Changed in 2021
(TRS
1035)
for
Follicular lymphoma
Changed in 2021
(TRS
1035)
for
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Changed in 2021
(TRS
1035)
for
Plasma cell myeloma
Changed in 2021
(TRS
1035)
for
Malignant neoplasms of prostate
Changed in 2021
(TRS
1035)
for
Lymphoid leukaemia, not elsewhere classified
Changed in 2021
(TRS
1035)
for
Diffuse large B-cell lymphomas
Changed in 2021
(TRS
1035)
for
Burkitt lymphoma including Burkitt leukaemia
Changed in 2021
(TRS
1035)
for
Hodgkin lymphoma
Therapeutic equivalent for
prednisolone
for
Allergic or hypersensitivity conditions of unspecified type
prednisolone for Follicular lymphoma, unspecified
prednisolone for Lymphoid leukaemia, not elsewhere classified
prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
prednisolone for Diffuse large B-cell lymphomas
prednisolone for Hodgkin lymphoma, unspecified
prednisolone for Burkitt lymphoma including Burkitt leukaemia
prednisolone for Plasma cell myeloma
prednisolone for Malignant neoplasms of prostate, unspecified
prednisolone for Follicular lymphoma, unspecified
prednisolone for Lymphoid leukaemia, not elsewhere classified
prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
prednisolone for Diffuse large B-cell lymphomas
prednisolone for Hodgkin lymphoma, unspecified
prednisolone for Burkitt lymphoma including Burkitt leukaemia
prednisolone for Plasma cell myeloma
prednisolone for Malignant neoplasms of prostate, unspecified
Wikipedia
DrugBank